KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Assets (2016 - 2025)

Travere Therapeutics' Non-Current Assets history spans 13 years, with the latest figure at $167.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 5.52% year-over-year to $167.6 million; the TTM value through Dec 2025 reached $685.5 million, down 5.02%, while the annual FY2025 figure was $167.6 million, 5.52% down from the prior year.
  • Non-Current Assets reached $167.6 million in Q4 2025 per TVTX's latest filing, roughly flat from $167.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $203.3 million in Q1 2023 to a low of $146.6 million in Q3 2023.
  • Average Non-Current Assets over 5 years is $183.8 million, with a median of $184.3 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: dropped 23.39% in 2023, then rose 22.54% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $193.8 million in 2021, then dropped by 3.95% to $186.1 million in 2022, then dropped by 7.53% to $172.1 million in 2023, then grew by 3.07% to $177.4 million in 2024, then dropped by 5.52% to $167.6 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Non-Current Assets are $167.6 million (Q4 2025), $167.5 million (Q3 2025), and $175.7 million (Q2 2025).